English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Early, complete, and sustained myocardial reperfusion is the principal goal of thrombolytic therapy. Unfortunately, the majority of patients treated today experience substantial delay before the initiation of thrombolytic therapy and, once treated, demonstrate suboptimal results of coronary thrombolysis. This is attributable, in part, to the underlying thrombus, which is platelet rich and resistant to plasminogen activators, and to the pro-thrombotic effects of fibrinolytics, which have no favourable effect on thrombin. Future therapeutic interventions will focus on improved reperfusion. Pharmacological strategies including novel plasminogen activators, direct thrombin inhibitors, and platelet glycoprotein IIb/IIIa inhibitors have all generated encouraging early clinical trial data and await further study. Mechanical reperfusion therapy with primary balloon angioplasty is particularly effective; its use is associated with the establishment of more complete infarct vessel patency than are thrombolytics. Considerable potential for the improvement of current reperfusion-directed therapy exists.

Early myocardial reperfusion: An assessment of current strategies in acute myocardial infarction